AusBiotech continues its call for further tax reform in Australia

4 March 2014

Building on the strategic plan that was presented at AusBiotech national conference last November by AusBiotech chairperson, Deborah Rathjen, the trade group is continuing its call for further tax reform in Australia.

AusBiotech advocates making tax incentives an asset for innovation and business, with four pillars:

Retain the Research & Development (R&D) Tax Incentive, which is a top priority for the life sciences industry;
Introduce the AIM Incentive, a “patent box”-style incentive to keep home-grown intellectual property (IP) once it reaches commercialization, as well as associated manufacturing, in Australia;
Introduce fiscal incentives for investors in pre-revenue and start-up companies; and
Restore the Employee Share Scheme (ESS) to its pre-2009 form.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >